GLPwatch
Papers (10410)
Page 135 of 174, ranked by citation count.
- Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
- A new era in obesity treatment.
- Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction.
- Intragastric injection botulinum toxin A for obesity management with or without liraglutide.
- Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity.
- [Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine].
- Is liraglutide a useful addition to diabetes therapy?
- Liraglutide upregulates the Cftr gene and regulates the mucus transcriptome profile in Brunner's glands in mice.
- A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.
- Diabetes: Cardiovascular benefits of semaglutide.
- Liraglutide combined with HIIT preserves contractile apparatus and blunts the progression of heart failure in diabetic cardiomyopathy rats.
- [Modern strategies for the treatment of childhood obesity].
- Exendin-4 protects the dopaminergic neurons by attenuating inflammatory responses of microglial cells via activation of AMPK.
- Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.
- Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats.
- Developing a novel algorithm to identify incident and prevalent dementia in Medicare claims-the ARIC Study.
- Semaglutide: FDA publishes warning amid reports of patients overdosing.
- Comparative Outcomes of Tirzepatide and Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes.
- Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy.
- Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.
- A case report of severe adverse reaction of exenatide: Anaphylactic shock.
- Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia.
- A call to update anesthetic protocols: the hidden risks of semaglutide.
- Unlocking the potential of microfluidic assisted formulation of exenatide-loaded solid lipid nanoparticles.
- A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.
- Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?
- Clinical trials for adolescent obesity: cooking up an alphabet stew of what to do.
- [The protective effect of exenatide on the renal injury in diabetic rats].
- The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.
- Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.
- Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes.
- More on Semaglutide in Early Type 1 Diabetes.
- GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
- [Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].
- A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.
- Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study.
- People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.
- Utilization of antiobesity medications within the Military Health System.
- Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.
- Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss.
- Therapy for HFpEF: A step forward brings new hope for people with obesity and diabetes.
- Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.
- Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison.
- Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.
- Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.
- One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.
- Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening.
- Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.
- Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
- Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
- Clinical studies on anti-obesity medications in Arab countries.
- Semaglutide in NASH-related cirrhosis: still a long way to go? - Authors' reply.
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
- Recognizing overweight and obesity as chronic diseases and acknowledging root causes.
- Advancing Diabetes Management and Glycemic Control While Exploring CagriSema's Impact on Obesity Management.
- Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.
- Case Report: Rhabdomyolysis following initiation of tirzepatide.
- Exendin-4 intervention attenuates atherosclerosis severity by modulating myeloid-derived suppressor cells and inflammatory cytokines in ApoE<sup>-/-</sup> mice.